Supply Chain Archives
07/30/2025
Beyond Logistics: Why Clinical Trial Success Depends on a Connected Supply Chain Strategy
Contract Research Organizations (CROs) are the orchestrators of modern clinical trials. From protocol development to site management and data collection, they serve as the hidden infrastructure that brings therapies from bench to bedside. But in the increasingly global and complex research landscape, a CRO’s ability to execute doesn’t just depend on clinical expertise, it hinges on the strength of the supply chain supporting every material movement and site milestone.
07/29/2025
Helping CROs Strengthen Performance Through Smarter Supply Chain Strategy
The complexity of clinical trials only continues to rise, especially in areas like cell and gene therapy (CGT), where the stakes are higher and timelines tighter. Contract Research Organizations (CROs) are navigating this shift from the front lines, carefully managing operational timelines and supporting regulatory readiness while ensuring their sponsor clients receive high-quality, compliant outcomes across global sites.
06/13/2025
Expanding Clinical Trials Internationally in the ATMP Space
Expanding an advanced therapy clinical trial internationally is an exciting milestone but can be daunting for researchers and biotech teams. International trials involve challenges like country-specific regulations, Qualified Person (QP) release, and complex logistics. Early planning for these issues can help avoid delays and ensure progress.
04/18/2025
Transforming Patient Access to CGT: Q&A with Aruna Mor
Aruna Mor, Chief Commercial Officer at Cryoport Systems, recently delivered a powerful keynote at Advanced Therapies Congress in London, shedding light on the complexities of patient access and the critical steps needed to overcome these barriers. We sat down with her to delve deeper into some of the key themes of her keynote, exploring the intersection of science, logistics, supply chain, regulation, and collaboration that will determine the future of Cell and Gene Therapy (CGT).
04/14/2025
Enabling the Outcome Through Enhancing Patient Accessibility
Cell and Gene Therapy (CGT) has emerged as one of the most transformative areas in modern medicine, shaping the future of healthcare and changing the face of next-generation therapeutic approaches. Yet, despite the continued scientific progress, a critical challenge persists in ensuring these therapies are accessible to the patients who need them most. This challenge was the focus of the keynote address at the Advanced Therapies Congress in London, delivered by Aruna Mor, Chief Commercial Officer at Cryoport Systems, where she spoke about to the state of patient access within the field of advanced therapeutics.
03/24/2025
Strengthening Global ATMP Logistics: How Cryoport Systems’ Netherlands Facility Supports Temperature-Controlled Supply Chains
The success of ATMPs depends on more than just scientific breakthroughs, it requires a highly controlled, risk-mitigated supply chain that ensures product integrity from research through commercialization. With cell and gene therapies moving across multiple clinical sites, manufacturing facilities, and regulatory jurisdictions, developers need a logistics partner that can support seamless, temperature-controlled supply chain management at a global scale.
03/21/2025
Strengthening ATMP Development in Europe: How BioServices Centers in France Enable Efficiency and Scalability
As Advanced Therapy Medicinal Product (ATMP) developers progress from early-stage research to late-phase clinical trials and commercialization, biostorage, sample management, and regulatory-compliant logistics become increasingly complex. Efficiently managing these critical components is essential to ensure product integrity, regulatory compliance, and seamless supply chain operations.
03/21/2025
Optimizing ATMP Cryopreservation: How IntegriCell™ Services in Belgium Ensure Cell Viability and Supply Chain Integrity
Cryopreservation is quickly becoming a critical yet often underestimated component of the Advanced Therapy Medicinal Product (ATMP) supply chain. The success of cell-based therapies depends on maintaining cell viability, stability, and consistency, yet variability in cryopreservation methods has compromised therapeutic outcomes.
03/12/2025
